Borislava Mihaylova

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals

Andrew Briggs, Sarah Parish, Alastair Gray, 2005, The Lancet.

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people

Andrew Briggs, Sarah Parish, Alastair Gray, 2006, BMJ : British Medical Journal.

Socioeconomic differences in health-care use and outcomes for stroke and ischaemic heart disease in China during 2009–16: a prospective cohort study of 0·5 million adults

Jun Lv, Robert Clarke, Derrick Bennett, 2020, The Lancet. Global health.

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

John Fuller, Luigi Tavazzi, John Wikstrand, 2019, The Lancet.

Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study

Andrew Briggs, Mark Sculpher, Roberto Ferrari, 2006, Heart.

The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials

Benjamin Thorpe, Isabelle L Smith, Julian P. T. Higgins, 2017, Trials.

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease

William Herrington, Colin Baigent, Alastair Gray, 2017, Heart.

Review of Statistical Methods for Analysing Healthcare Resources and Costs

Anthony O'Hagan, Andrew Briggs, Simon G Thompson, 2010, Health economics.